Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024 - Episode 1

Testing for ALK Fusions and ROS1 Rearrangements in NSCLC

,

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.